3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
58
Neoplasm Metastasis
21
Carcinoma, Non-Small-Cell Lung
9
Stomach Neoplasms
8
Brain Neoplasms
8
Colorectal Neoplasms
7
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
Neoplasms
3
Esophageal Neoplasms
3
Advanced Breast Cancer
3
Adenocarcinoma
3
Prostatic Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Gastric Cancer
2
Colonic Neoplasms
2
Breast Cancer With Brain Metastasis
2
Advanced Solid Tumor
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Interventions
pembrolizumab
141
Nivolumab
117
Ipilimumab
69
Cyclophosphamide
34
Specimen Handling
31
Magnetic Resonance Spectroscopy
28
trametinib
23
fludarabine
22
binimetinib
22
Interleukin-2
21
dabrafenib
19
relatlimab
17
encorafenib
17
Biopsy
17
aldesleukin
16
CTLA-4 Antigen
16
fludarabine phosphate
15
cemiplimab
15
atezolizumab
15
Radiosurgery
15
Opdualag
14
Radiotherapy
11
lifileucel
10
lenvatinib
10
Blood Specimen Collection
10
spartalizumab
8
Paclitaxel
8
Cisplatin
8
Bevacizumab
8
cobimetinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
trastuzumab deruxtecan
×
1 year
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled